Managing the adverse effects of clozapine

by Dr James MacCabe and Dr Jennifer Brook

 

Last updated: January 2016

 

Clozapine was the first 'atypical' antipsychotic, notable for its unique effectiveness in refractory cases of schizophrenia as well as the absence of extra pyramidal side-effects and tardive dyskinesia (Tandon, 2011). For some time its use was limited by serious adverse effects, including agranulocytosis, but improved monitoring has led to its reintroduction for treatment-resistant schizophrenia. In fact, clozapine has been shown to reduce mortality compared to other antipsychotics (Tiihonen et al, 2009).

 

Clozapine is currently recommended in NICE guidelines (2009) for use in schizophrenia where two previous antipsychotics have been ineffective (treatment-resistant), which occurs in around 30% of patients. Clozapine improves outcomes in around 50–60% of these patients (Meltzer, 1997). Despite this, concerns over adverse effects may cause a premature withdrawal of this highly effective treatment, or a delay in initiation of around four years (Howes et al, 2012).

 

This module aims to improve understanding of the adverse effects which may arise from clozapine use, increase confidence in alleviating them and suggest management strategies.

 

Start the module

 

 

If you like this module, you may also be interested in:

 

Metabolic syndrome and schizophrenia by Dr Arijit Bose and Dr Sepehr Hafizi

 

The pharmacological treatment of resistant depression – an overview by Professor Philip J. Cowen

 

The pharmacological management of mania by Dr Karine A.N. Macritchie and Professor Allan H. Young

 

The pharmacological management of anxiety disorders by Dr Zia Nadeem and Dr Allan Scott

 

 

BJPsych Advances: related articles for CPD Online

 

 

Related Advances articles

 

Download take-home notes to print and annotateDownload take-home notes to print and annotate

 

© 2017 Royal College of Psychiatrists